Inhibitor of 5α-reductase, the enzyme which converts testosterone to the more potent androgen, 5α-dihydrotestosterone. Prepn: G. H. Rasmusson, G. F. Reynolds, EP 155096; eidem, US 4760071 (1985, 1988 both to Merck & Co.); G. H. Rasmusson et al., J. Med. Chem. 29, 2298 (1986); A. Bhattacharya et al., J. Am. Chem. Soc. 110, 3318 (1988). HPLC determn in plasma and urine: J. R. Carlin et al., J. Chromatogr. 427, 79 (1988). Review of pharmacology and clinical uses: S. L. Sudduth, M. J. Koronkowski, Pharmacotherapy 13, 309-329 (1993). Clinical trials in benign prostatic hyperplasia: J. L. Tenover et al., Clin. Ther. 19, 243 (1997); J. D. McConnell et al., N. Engl. J. Med. 338, 557 (1998); in male pattern hair loss: K. D. Kaufman et al., J. Am. Acad. Dermatol. 39, 578 (1998). Review of use in benign prostatic hyperplasia: J. E. Edwards, R. A. Moore, BMC Urol. 2, 14 (2002); in alopecia: J. F. Libecco, W. F. Bergfeld, Expert Opin. Pharmacother. 5, 933-940 (2004); in prevention of prostate cancer: E. D. Canby-Hagino et al., ibid. 7, 899-905 (2006).
In treatment of benign prostatic hypertrophy. Antialopecia agent.
Antialopecia Agent; Antiprostatic Hypertrophy; 5α-Reductase Inhibitor